Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB308 + Zimberelimab in Advanced Malignancies
NCT04772989Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Mar 2021
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of ralzapastotug in solid tumor, non-small cell lung cancer (NSCLC), melanoma and 6 more (8 arms), sponsored by Arcus Biosciences. Primary endpoints: Percentage of participants with Adverse Events and Percentage of participants who experience a Dose Limiting Toxicity. Started Mar 2021; status: completed.
02
Drugs
ralzapastotug
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)melanomaCervical Cancer (CC)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04772989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04772989.